The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.
At all time points, consistently high levels of patient satisfaction were observed (>84% reporting much or very much improved).
The health system defended itself by claiming it had done nothing wrong, and that Dr T had a clear duty to inform it of the ...
(HealthDay News) — Increased consumption of dark chocolate, but not milk chocolate, is associated with a reduced risk for type 2 diabetes (T2D), according to a study published online Dec. 4 in The BMJ ...
Tiragolumab is a novel immune checkpoint inhibitor that binds to TIGIT, a protein receptor on immune cells, which suppresses ...
The single-arm, open-label APPULSE-PNH trial included 52 PNH patients who were on a stable regimen with either eculizumab or ravulizumab.
Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens.
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
(HealthDay News) — During August 2021 to August 2023, the overall prevalence of anemia was 9.3% among people aged 2 years and older, according to a December data brief published by the National Center ...
Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with lupus nephritis may reduce the risk of progression to end-stage kidney disease (ESKD), according to a poster presentation ...
According to the Company, the premixed bags were developed to reduce preparation time and the risk of preparation errors.
(HealthDay News) — Many general practitioners prescribe antibiotics for suspected community-acquired pneumonia (CAP) even when chest radiograph (CR) results are negative, according to a study ...